Cas:118458-20-1 yttrium isopropoxide oxide manufacturer & supplier

Chemical Name:yttrium isopropoxide oxide

CAS.NO:118458-20-1

Synonyms:TRIDECAKIS(ISOPROPANOLATO)(OXO)PENTAYTTRIUM;Tridecaisopropanolatooxopentayttrium;yttrium oxide isopropoxide;Yttrium (III) i-propoxide oxide;MFCD00134499

Molecular Formula:C₃₉H₉₁O₁₄Y₅

Molecular Weight:1228.66000

HS Code:

Physical and Chemical Properties:

Melting point:N/A

Boiling point:N/A

Density:N/A

Index of Refraction:

PSA:137.06000

Exact Mass:1228.17000

LogP:11.26530

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:UN 2925 4.1/PG 2

Packing Group:II

Contact us for information like TRIDECAKIS(ISOPROPANOLATO)(OXO)PENTAYTTRIUM chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,MFCD00134499 physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,TRIDECAKIS(ISOPROPANOLATO)(OXO)PENTAYTTRIUM Use and application,yttrium oxide isopropoxide technical grade,usp/ep/jp grade.

Related News: At the same time, because the profits of a single variety of characteristic APIs do not have long-term growth, companies need more product reserves. yttrium isopropoxide oxide manufacturer At the same time, because the profits of a single variety of characteristic APIs do not have long-term growth, companies need more product reserves. yttrium isopropoxide oxide supplier The use of contrast agents is different from other drugs, and it needs to be used with corresponding equipment. In recent years, China is in the growth period of imaging equipment. yttrium isopropoxide oxide vendor The Company��s first-of-kind approach involves engineering human iPSCs in a one-time genetic modification event and selecting a single engineered iPSC for maintenance as a clonal master iPSC line. yttrium isopropoxide oxide factory Trial results demonstrated that Oligomannate statistically improved cognitive function in mild-to-moderate AD patients as early as week 4 and the benefit was sustained at each follow-up assessment visit,�� Shanghai Green Valley Pharmaceuticals, which developed the drug along with two academic institutions in China, said in a statement.